½ÃÀ庸°í¼­
»óǰÄÚµå
1595264

°æÇÇÀû ½ÅÀå °á¼® Á¦°Å¼ú ½ÃÀå : ±¸¼º¿ä¼Ò, À¯Çü ¹× ÃÖÁ¾ »ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Percutaneous Nephrolithotomy Market by Component (Accessories, Devices, Services), Type (Micro-Percutaneous Nephrolithotomy, Mini Percutaneous Nephrolithotomy, Ultra-Mini Percutaneous Nephrolithotomy), End-Users - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 189 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

°æÇÇÀû ½ÅÀå °á¼® Á¦°Å¼ú ½ÃÀåÀº 2023³â¿¡ 183¾ï 5,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 196¾ï 6,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 7.90%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 312¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù.

°æÇÇÀû ½ÅÀå °á¼® Á¦°Å¼ú(PCNL)Àº ü¿Ü Ãæ°ÝÆÄ °á¼® ÆÄ¼â¼úÀ̳ª ¿ä°ü°æ °Ë»ç µî ´Ù¸¥ Ä¡·á¹ýÀ¸·Î´Â ³Ê¹« Å« ½ÅÀå °á¼®À» Á¦°ÅÇϱâ À§ÇØ °í¾ÈµÈ ÃÖ¼Ò Ä§½ÀÀû ¼ö¼ú ¹æ¹ýÀÔ´Ï´Ù. PCNLÀÇ Çʿ伺Àº ÁÖ·Î Å« ½ÅÀå °á¼®À̳ª º¹ÀâÇÑ ½ÅÀå °á¼®ÀÌ Àç¹ß¼º °¨¿°, ½ÉÇÑ ÅëÁõ, ¿ä·Î ¸·ÈûÀ» À¯¹ßÇÏ´Â °æ¿ì, PCNLÀº ÁÖ·Î ÀüÅëÀûÀÎ ¹æ¹ýÀÌ ½ÇÆÐÇÑ °æ¿ì¿¡ Àû¿ëµÇ¸ç ºñ´¢±â°ú Áø·á¼Ò, º´¿ø, Àü¹® Ŭ¸®´Ð¿¡¼­ ÇʼöÀûÀÎ Ä¡·á¹ýÀÔ´Ï´Ù. Ŭ¸®´Ð¿¡¼­ ÇʼöÀûÀ¸·Î »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÃÖÁ¾ »ç¿ë ¹üÀ§¿¡´Â ¼÷·ÃµÈ ÀÇ»ç¿Í °í±Þ ¿µ»ó ó¸® µµ±¸¸¦ °®Ãá ¸¹Àº ÀÇ·á ½Ã¼³ÀÌ Æ÷ÇԵ˴ϴÙ. ½ÃÀå ÀλçÀÌÆ®¿¡ µû¸£¸é, »ýȰ½À°ü ¹× ½Ä½À°üÀ¸·Î ÀÎÇÑ ½ÅÀå °á¼® À¯º´·ü Áõ°¡´Â ÀÇ·á ÁöÃâ Áõ°¡¿Í ÇÔ²² PCNL ¼ö¿ä¸¦ Å©°Ô °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ¼ö¼ú ÀåºñÀÇ ±â¼ú ¹ßÀü°ú ¼ö¼ú ÈÄ °á°úÀÇ °³¼±Àº ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀáÀçÀûÀÎ ºñÁî´Ï½º ±âȸ´Â ÀÇ·á ½Ã½ºÅÛ È®ÀåÀÌ ¿¹»óµÇ´Â ½ÅÈï ½ÃÀå¿¡¼­ ãÀ» ¼ö ÀÖÀ¸¸ç, ¼ö¼ú Á¤È®µµ¸¦ ³ôÀ̱â À§ÇÑ ÀΰøÁö´É°ú ·Îº¿ °øÇп¡ ´ëÇÑ ÅõÀÚ´Â º¯È­¸¦ °¡Á®¿Ã ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª ³ôÀº ¼ö¼ú ºñ¿ë, Àü¹®Àû ÈÆ·ÃÀÇ Çʿ伺, ÃâÇ÷ ¹× °¨¿°°ú °°Àº ¼ö¼ú ÈÄ ÇÕº´Áõ°ú °°Àº °úÁ¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ±â¼ú Çõ½ÅÀÌ ÇÊ¿äÇÑ ºÐ¾ß·Î´Â ºñ¿ë È¿À²ÀûÀÎ ¼ö¼ú µµ±¸ÀÇ °³¹ß, ¿µ»ó ±â¼ú °­È­, ¼ö¼ú Á¢±Ù¼ºÀ» ³ôÀ̱â À§ÇÑ ±³À° ¸ðµâÀÇ ´Ü¼øÈ­ µîÀÌ ÀÖ½À´Ï´Ù. °á¼® Àç¹ß ¹æÁö¿¡ ´ëÇÑ ¿¬±¸´Â Å« »ç¾÷ ¼ºÀå Àü¸ÁÀ» °¡Á®´Ù ÁÙ ¼ö ÀÖ½À´Ï´Ù. ½ÃÀå °æÀïÀº °è¼ÓµÇ°í ÀÖÀ¸¸ç, ȯÀÚ °á°ú¿Í ºñ¿ë È¿À²¼º °³¼±¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ±â¼ú°ú ȯÀÚ Ä¡·áÀÇ ÇÏÀ̺긮µå¿¡ ÁßÁ¡À» µÎ´Â °ÍÀÌ Å« ÀÌÀÍÀ» °¡Á®´Ù ÁÙ ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼­ ÀÌÇØ°ü°èÀÚµéÀº Çõ½ÅÀûÀÎ ±â¼ú°ú ±³À° ÀÎÇÁ¶ó¿¡ ´ëÇÑ Àü·«À» Á¶Á¤ÇÏ¿© PCNLÀÇ ÀáÀçÀûÀÎ ½ÃÀå ÀÔÁö¸¦ ±Ø´ëÈ­ÇØ¾ß ÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ(2023) 183¾ï 5,000¸¸ ´Þ·¯
ÃßÁ¤ ¿¬µµ(2024³â) 196¾ï 6,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 312¾ï 5,000¸¸ ´Þ·¯
CAGR(%) 7.90%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â °æÇÇÀû ½ÅÀå °á¼® Á¦°Å¼ú ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ®¸¦ °ø°³ÇÕ´Ï´Ù.

°æÇÇÀû ½ÅÀå °á¼® Á¦°Å¼ú ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ¸·Î º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ º¯È­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«ÀûÀÎ ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • Àü ¼¼°è ½ÅÀå °á¼® ¹ß»ý Áõ°¡
    • º´ÀÇ Á¶±â Áø´Ü ¹× Ä¡·á·Î ±â¿ï¾îÁü
    • Àúħ½ÀÀû ÀÇ·á ½Ã¼ú¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • °æÇÇÀû ½ÅÀå °á¼® Á¦°Å¼ú ÀåºñÀÇ ±â¼úÀû ¹®Á¦¿Í °íºñ¿ë
  • ½ÃÀå ±âȸ
    • °æÇÇÀû ½ÅÀå °á¼® Á¦°Å¼úÀÇ Çõ½Å°ú Áøº¸
    • ÃʼÒÇü °æÇÇÀû ½ÅÀå °á¼® Á¦°Å¼ú¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¿¬±¸
  • ½ÃÀå °úÁ¦
    • °æÇÇÀû ½ÅÀå °á¼® Á¦°Å¼ú°ú °ü·ÃµÈ ÇÕº´Áõ ¹× À§Ç輺

Portre's Five Forces °æÇÇÀû ½ÅÀå °á¼® Á¦°Å¼ú ½ÃÀåÀ» Ž»öÇϱâ À§ÇÑ Àü·« µµ±¸

Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â °æÇÇÀû ½ÅÀå °á¼® Á¦°Å¼ú ½ÃÀå °æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â µ¥ Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : °æÇÇÀû ½ÅÀå °á¼® Á¦°Å¼ú ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº °æÇÇÀû ½ÅÀå °á¼® Á¦°Å¼ú ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® °æÇÇÀû ½ÅÀå °á¼® Á¦°Å¼ú ½ÃÀå¿¡¼­°æÀï ±¸µµ ÆÄ¾Ç

°æÇÇÀû ½ÅÀå °á¼® Á¦°Å¼ú ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­, ÅëÇÕÀÇ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º °æÇÇÀû ½ÅÀå °á¼® Á¦°Å¼ú ½ÃÀå¿¡¼­°ø±Þ¾÷ü ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â °æÇÇÀû ½ÅÀå °á¼® Á¦°Å¼ú ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

°æÇÇÀû ½ÅÀå °á¼® Á¦°Å¼ú ½ÃÀå¿¡¼­ ¼º°øÇϱâ À§ÇÑ Àü·« ºÐ¼® ¹× ±ÇÀå »çÇ×

°æÇÇÀû ½ÅÀå °á¼® Á¦°Å¼ú ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀº °æÀï ȯ°æÀÇ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ ü°è¸¦ ±¸ÃàÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

    Á¦6Àå °æÇÇÀû ½ÅÀå °á¼® Á¦°Å¼ú ½ÃÀå : ÄÄÆ÷³ÍÆ®º°

    • ¾×¼¼¼­¸®
    • µð¹ÙÀ̽º
    • ¼­ºñ½º

    Á¦7Àå °æÇÇÀû ½ÅÀå °á¼® Á¦°Å¼ú ½ÃÀå : À¯Çüº°

    • ¸¶ÀÌÅ©·Î °æÇǽÅÀå °á¼® ÀûÃâ¼ú
    • ¹Ì´Ï °æÇÇÀû ½ÅÀå °á¼® Á¦°Å¼ú
    • ¿ïÆ®¶ó ¹Ì´Ï °æÇÇÀû ½ÅÀå °á¼® Á¦°Å¼ú

    Á¦8Àå °æÇÇÀû ½ÅÀå °á¼® Á¦°Å¼ú ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

    • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
    • Ŭ¸®´Ð
    • º´¿ø

    Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ °æÇÇÀû ½ÅÀå °á¼® Á¦°Å¼ú ½ÃÀå

    • ¾Æ¸£ÇîÆ¼³ª
    • ºê¶óÁú
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
    • ¹Ì±¹

    Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °æÇÇÀû ½ÅÀå °á¼® Á¦°Å¼ú ½ÃÀå

    • È£ÁÖ
    • Áß±¹
    • Àεµ
    • Àεµ³×½Ã¾Æ
    • ÀϺ»
    • ¸»·¹À̽þÆ
    • Çʸ®ÇÉ
    • ½Ì°¡Æ÷¸£
    • Çѱ¹
    • ´ë¸¸
    • ű¹
    • º£Æ®³²

    Á¦11Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ °æÇÇÀû ½ÅÀå °á¼® Á¦°Å¼ú ½ÃÀå

    • µ§¸¶Å©
    • ÀÌÁýÆ®
    • Çɶõµå
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • À̽º¶ó¿¤
    • ÀÌÅ»¸®¾Æ
    • ³×´ú¶õµå
    • ³ªÀÌÁö¸®¾Æ
    • ³ë¸£¿þÀÌ
    • Æú¶õµå
    • īŸ¸£
    • ·¯½Ã¾Æ
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ½ºÆäÀÎ
    • ½º¿þµ§
    • ½ºÀ§½º
    • ÅÍŰ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • ¿µ±¹

    Á¦12Àå °æÀï ±¸µµ

    • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â
    • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023³â
    • °æÀï ½Ã³ª¸®¿À ºÐ¼®
    • Àü·« ºÐ¼®°ú Á¦¾È

    ±â¾÷ ¸®½ºÆ®

    • Advin Urology
    • Allengers Medical Systems Ltd.
    • Attikouris Enterprises Ltd.
    • Boston Scientific Corporation
    • Coloplast Corporation
    • Cook Group Incorporated
    • Dornier MedTech
    • E.M.S. Electro Medical Systems S.A.
    • EDAP TMS SA
    • ELMED Inc.
    • Envaste Limited
    • Karl Storz Se & Co. KG
    • Medical Device Business Services, Inc.
    • Medispec Ltd.
    • Olympus Corporation
    • Richard Wolf GmbH
    • Rocamed
    • Siemens AG
    • Stryker Corporation
    LSH

    The Percutaneous Nephrolithotomy Market was valued at USD 18.35 billion in 2023, expected to reach USD 19.66 billion in 2024, and is projected to grow at a CAGR of 7.90%, to USD 31.25 billion by 2030.

    Percutaneous Nephrolithotomy (PCNL) is a minimally invasive surgical procedure designed to remove kidney stones that are too large for other treatments like extracorporeal shock wave lithotripsy or ureteroscopy. It involves creating a small incision in the back through the skin to reach and extract the stone directly from the kidney. The necessity for PCNL arises primarily when large or complicated kidney stones cause recurrent infections, significant pain, or obstruction in the urinary tract. It is primarily applied in procedures where traditional methods fail, making it vital in urology practices, hospitals, and specialized clinics. The end-use scope prominently includes healthcare facilities with skilled practitioners and advanced imaging tools. Market insights reveal that a growing global prevalence of kidney stones, attributed to lifestyle factors and dietary habits, alongside increasing healthcare expenditures, is significantly driving PCNL demand. Technological advancements in surgical devices and improved postoperative outcomes further buoy market growth. Potential opportunities lie in emerging markets with healthcare systems poised for expansion, and investments in artificial intelligence and robotics to enhance surgical precision can be transformative. However, market growth faces challenges like the high cost of the procedure, the requirement for specialized training, and postoperative complications like bleeding or infection. Areas ripe for innovation include the development of more cost-effective surgical tools, enhanced imaging technologies, and simplified training modules to broaden procedure accessibility. Research into preventing stone recurrence could offer significant business growth prospects. The market remains competitive, with a growing emphasis on improving patient outcomes and cost-efficiency, suggesting a hybrid focus on technology and patient care can yield substantial returns. Thus, stakeholders should align their strategies to innovative technologies and training infrastructure to maximize the potential of PCNL's expanding market presence.

    KEY MARKET STATISTICS
    Base Year [2023] USD 18.35 billion
    Estimated Year [2024] USD 19.66 billion
    Forecast Year [2030] USD 31.25 billion
    CAGR (%) 7.90%

    Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Percutaneous Nephrolithotomy Market

    The Percutaneous Nephrolithotomy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

    • Market Drivers
      • Rising incidences of kidney stones among individuals worldwide
      • Inclination towards early diagnosis and treatment of medical conditions
      • Growing preference towards minimally invasive medical procedures
    • Market Restraints
      • Technical issues and high cost of percutaneous nephrolithotomy equipment
    • Market Opportunities
      • Innovations and advancements in percutaneous nephrolithotomy
      • Ongoing research on ultra-mini-percutaneous nephrolithotomy
    • Market Challenges
      • Complications and risks associated with percutaneous nephrolithotomy

    Porter's Five Forces: A Strategic Tool for Navigating the Percutaneous Nephrolithotomy Market

    Porter's five forces framework is a critical tool for understanding the competitive landscape of the Percutaneous Nephrolithotomy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

    PESTLE Analysis: Navigating External Influences in the Percutaneous Nephrolithotomy Market

    External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Percutaneous Nephrolithotomy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

    Market Share Analysis: Understanding the Competitive Landscape in the Percutaneous Nephrolithotomy Market

    A detailed market share analysis in the Percutaneous Nephrolithotomy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

    FPNV Positioning Matrix: Evaluating Vendors' Performance in the Percutaneous Nephrolithotomy Market

    The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Percutaneous Nephrolithotomy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

    Strategy Analysis & Recommendation: Charting a Path to Success in the Percutaneous Nephrolithotomy Market

    A strategic analysis of the Percutaneous Nephrolithotomy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

    Key Company Profiles

    The report delves into recent significant developments in the Percutaneous Nephrolithotomy Market, highlighting leading vendors and their innovative profiles. These include Advin Urology, Allengers Medical Systems Ltd., Attikouris Enterprises Ltd., Boston Scientific Corporation, Coloplast Corporation, Cook Group Incorporated, Dornier MedTech, E.M.S. Electro Medical Systems S.A., EDAP TMS SA, ELMED Inc., Envaste Limited, Karl Storz Se & Co. KG, Medical Device Business Services, Inc., Medispec Ltd., Olympus Corporation, Richard Wolf GmbH, Rocamed, Siemens AG, and Stryker Corporation.

    Market Segmentation & Coverage

    This research report categorizes the Percutaneous Nephrolithotomy Market to forecast the revenues and analyze trends in each of the following sub-markets:

    • Based on Component, market is studied across Accessories, Devices, and Services.
    • Based on Type, market is studied across Micro-Percutaneous Nephrolithotomy, Mini Percutaneous Nephrolithotomy, and Ultra-Mini Percutaneous Nephrolithotomy.
    • Based on End-Users, market is studied across Ambulatory Surgical Centers, Clinics, and Hospitals.
    • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

    The report offers a comprehensive analysis of the market, covering key focus areas:

    1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

    2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

    3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

    4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

    5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

    The report also answers critical questions to aid stakeholders in making informed decisions:

    1. What is the current market size, and what is the forecasted growth?

    2. Which products, segments, and regions offer the best investment opportunities?

    3. What are the key technology trends and regulatory influences shaping the market?

    4. How do leading vendors rank in terms of market share and competitive positioning?

    5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

    Table of Contents

    1. Preface

    • 1.1. Objectives of the Study
    • 1.2. Market Segmentation & Coverage
    • 1.3. Years Considered for the Study
    • 1.4. Currency & Pricing
    • 1.5. Language
    • 1.6. Stakeholders

    2. Research Methodology

    • 2.1. Define: Research Objective
    • 2.2. Determine: Research Design
    • 2.3. Prepare: Research Instrument
    • 2.4. Collect: Data Source
    • 2.5. Analyze: Data Interpretation
    • 2.6. Formulate: Data Verification
    • 2.7. Publish: Research Report
    • 2.8. Repeat: Report Update

    3. Executive Summary

    4. Market Overview

    5. Market Insights

    • 5.1. Market Dynamics
      • 5.1.1. Drivers
        • 5.1.1.1. Rising incidences of kidney stones among individuals worldwide
        • 5.1.1.2. Inclination towards early diagnosis and treatment of medical conditions
        • 5.1.1.3. Growing preference towards minimally invasive medical procedures
      • 5.1.2. Restraints
        • 5.1.2.1. Technical issues and high cost of percutaneous nephrolithotomy equipment
      • 5.1.3. Opportunities
        • 5.1.3.1. Innovations and advancements in percutaneous nephrolithotomy
        • 5.1.3.2. Ongoing research on ultra-mini-percutaneous nephrolithotomy
      • 5.1.4. Challenges
        • 5.1.4.1. Complications and risks associated with percutaneous nephrolithotomy
    • 5.2. Market Segmentation Analysis
    • 5.3. Porter's Five Forces Analysis
      • 5.3.1. Threat of New Entrants
      • 5.3.2. Threat of Substitutes
      • 5.3.3. Bargaining Power of Customers
      • 5.3.4. Bargaining Power of Suppliers
      • 5.3.5. Industry Rivalry
    • 5.4. PESTLE Analysis
      • 5.4.1. Political
      • 5.4.2. Economic
      • 5.4.3. Social
      • 5.4.4. Technological
      • 5.4.5. Legal
      • 5.4.6. Environmental

    6. Percutaneous Nephrolithotomy Market, by Component

    • 6.1. Introduction
    • 6.2. Accessories
    • 6.3. Devices
    • 6.4. Services

    7. Percutaneous Nephrolithotomy Market, by Type

    • 7.1. Introduction
    • 7.2. Micro-Percutaneous Nephrolithotomy
    • 7.3. Mini Percutaneous Nephrolithotomy
    • 7.4. Ultra-Mini Percutaneous Nephrolithotomy

    8. Percutaneous Nephrolithotomy Market, by End-Users

    • 8.1. Introduction
    • 8.2. Ambulatory Surgical Centers
    • 8.3. Clinics
    • 8.4. Hospitals

    9. Americas Percutaneous Nephrolithotomy Market

    • 9.1. Introduction
    • 9.2. Argentina
    • 9.3. Brazil
    • 9.4. Canada
    • 9.5. Mexico
    • 9.6. United States

    10. Asia-Pacific Percutaneous Nephrolithotomy Market

    • 10.1. Introduction
    • 10.2. Australia
    • 10.3. China
    • 10.4. India
    • 10.5. Indonesia
    • 10.6. Japan
    • 10.7. Malaysia
    • 10.8. Philippines
    • 10.9. Singapore
    • 10.10. South Korea
    • 10.11. Taiwan
    • 10.12. Thailand
    • 10.13. Vietnam

    11. Europe, Middle East & Africa Percutaneous Nephrolithotomy Market

    • 11.1. Introduction
    • 11.2. Denmark
    • 11.3. Egypt
    • 11.4. Finland
    • 11.5. France
    • 11.6. Germany
    • 11.7. Israel
    • 11.8. Italy
    • 11.9. Netherlands
    • 11.10. Nigeria
    • 11.11. Norway
    • 11.12. Poland
    • 11.13. Qatar
    • 11.14. Russia
    • 11.15. Saudi Arabia
    • 11.16. South Africa
    • 11.17. Spain
    • 11.18. Sweden
    • 11.19. Switzerland
    • 11.20. Turkey
    • 11.21. United Arab Emirates
    • 11.22. United Kingdom

    12. Competitive Landscape

    • 12.1. Market Share Analysis, 2023
    • 12.2. FPNV Positioning Matrix, 2023
    • 12.3. Competitive Scenario Analysis
    • 12.4. Strategy Analysis & Recommendation

    Companies Mentioned

    • 1. Advin Urology
    • 2. Allengers Medical Systems Ltd.
    • 3. Attikouris Enterprises Ltd.
    • 4. Boston Scientific Corporation
    • 5. Coloplast Corporation
    • 6. Cook Group Incorporated
    • 7. Dornier MedTech
    • 8. E.M.S. Electro Medical Systems S.A.
    • 9. EDAP TMS SA
    • 10. ELMED Inc.
    • 11. Envaste Limited
    • 12. Karl Storz Se & Co. KG
    • 13. Medical Device Business Services, Inc.
    • 14. Medispec Ltd.
    • 15. Olympus Corporation
    • 16. Richard Wolf GmbH
    • 17. Rocamed
    • 18. Siemens AG
    • 19. Stryker Corporation
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦